Fedin A I
Pirogov Russian National Research Medical University, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(1):30-36. doi: 10.17116/jnevro20181181130-36.
To study the dynamics of cognitive impairment in patients with chronic cerebral ischemia (CCI) treated with cortexin and memantinol (memantine).
The authors present the results of the multicenter observational program 'KORMEN' that studied the efficacy of cortexin and memantinol in the treatment of cognitive impairment in patients with CCI. The study included 495 patients, 204 (41.2%) men and 291 (58.8%) women. Patients were stratified into two groups: cortexin group (n=388 (78.4%)) and cortexin + memantinol group.
A significant positive effect of treatment based on the scores on 4 cognitive scales was shown in both groups of patients. The addition of memantinol significantly improved cognitive functions in patients with severe cognitive impairment (р<0.05). The safety profile of the drugs was confirmed.
研究用皮质素和美金刚（美金刚胺）治疗慢性脑缺血（CCI）患者时认知障碍的动态变化。
作者展示了多中心观察项目“KORMEN”的结果，该项目研究了皮质素和美金刚在治疗CCI患者认知障碍方面的疗效。该研究纳入了495例患者，其中男性204例（41.2%），女性291例（58.8%）。患者被分为两组：皮质素组（n = 388例（78.4%））和皮质素+美金刚组。
两组患者基于4种认知量表评分的治疗均显示出显著的积极效果。添加美金刚显著改善了重度认知障碍患者的认知功能（р<0.05）。证实了这些药物的安全性。
